ECR: dose reduzida de anticoagulantes orais pode ser uma opção mais segura do que os antagonistas de vitamina K em pacientes em hemodiálise com fibrilação atrial

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial – Journal of the American Society of Nephrology (link para o resumo – $ para o texto completo)

Comentário no Twitter

This study finds that patients on hemodialysis with atrial fibrillation experienced decreased cardiovascular events and major bleeding complications with direct oral anticoagulants compared with vitamin K antagonists https://t.co/6FOKkEXtfN pic.twitter.com/PD6qHaeZjT

— JASN_News (@JASN_News) March 22, 2021